Iyer V, Saberi S, Pacheco R, Sizemore E, Stockman S, Kulkarni A
Neuropharmacology. 2024; 257:110052.
PMID: 38936657
PMC: 11261750.
DOI: 10.1016/j.neuropharm.2024.110052.
Essmat N, Karadi D, Zador F, Kiraly K, Furst S, Al-Khrasani M
Molecules. 2023; 28(23).
PMID: 38067494
PMC: 10708112.
DOI: 10.3390/molecules28237766.
Liu S, Patanwala A, Naylor J, Levy N, Knaggs R, Stevens J
Anaesthesia. 2023; 78(10):1237-1248.
PMID: 37365700
PMC: 10952779.
DOI: 10.1111/anae.16070.
Villavicencio A, Taha H, Burneikiene S
Neurosurg Rev. 2023; 46(1):97.
PMID: 37106209
DOI: 10.1007/s10143-023-02011-6.
Wong A, Grobler A, Le B
Contemp Clin Trials Commun. 2022; 30:101036.
PMID: 36407843
PMC: 9672918.
DOI: 10.1016/j.conctc.2022.101036.
Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain.
BouSaba J, Sannaa W, Camilleri M
Therap Adv Gastroenterol. 2022; 15:17562848221078638.
PMID: 35509419
PMC: 9058332.
DOI: 10.1177/17562848221078638.
Antinociceptive and Anti-Inflammatory Effects of Recombinant Crotamine in Mouse Models of Pain.
Park J, Do B, Lee J, Yang H, Nguyen A, Krupa M
Toxins (Basel). 2021; 13(10).
PMID: 34679000
PMC: 8538437.
DOI: 10.3390/toxins13100707.
Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation.
Lemaire A, Pointreau Y, Narciso B, Piloquet F, Braniste V, Sabate J
Support Care Cancer. 2021; 29(12):7577-7586.
PMID: 34120247
PMC: 8549935.
DOI: 10.1007/s00520-021-06299-2.
Predictive Models to Identify Small Molecule Activators and Inhibitors of Opioid Receptors.
Sakamuru S, Zhao J, Xia M, Hong H, Simeonov A, Vaisman I
J Chem Inf Model. 2021; 61(6):2675-2685.
PMID: 34047186
PMC: 9447431.
DOI: 10.1021/acs.jcim.1c00439.
The cannabinoid CB receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence.
Iyer V, Slivicki R, Thomaz A, Crystal J, Mackie K, Hohmann A
Eur J Pharmacol. 2020; 886:173544.
PMID: 32896549
PMC: 7694697.
DOI: 10.1016/j.ejphar.2020.173544.
Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor - NARCOTIC trial.
Niezgoda P, Baranska M, Sikora J, Sobczak P, Buszko K, Sikora A
Cardiol J. 2020; 29(3):432-440.
PMID: 32207836
PMC: 9170314.
DOI: 10.5603/CJ.a2020.0040.
Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits.
Camilleri M, Lembo A, Katzka D
Clin Gastroenterol Hepatol. 2017; 15(9):1338-1349.
PMID: 28529168
PMC: 5565678.
DOI: 10.1016/j.cgh.2017.05.014.
Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B
Eur J Pain. 2017; 21(9):1485-1494.
PMID: 28474460
PMC: 5655918.
DOI: 10.1002/ejp.1050.
Laxatives Do Not Improve Symptoms of Opioid-Induced Constipation: Results of a Patient Survey.
Emmanuel A, Johnson M, McSkimming P, Dickerson S
Pain Med. 2017; 18(10):1932-1940.
PMID: 28339544
PMC: 5914325.
DOI: 10.1093/pm/pnw240.
Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations.
Ueberall M, Mueller-Schwefe G
J Pain Res. 2016; 9:1001-1020.
PMID: 27881925
PMC: 5115682.
DOI: 10.2147/JPR.S112418.
Opioid-Induced Constipation among a Convenience Sample of Patients with Cancer Pain.
Coyne K, Sexton C, LoCasale R, King F, Margolis M, Ahmedzai S
Front Oncol. 2016; 6:131.
PMID: 27376025
PMC: 4896913.
DOI: 10.3389/fonc.2016.00131.
Opioid-induced Hallucinations: A Review of the Literature, Pathophysiology, Diagnosis, and Treatment.
Sivanesan E, Gitlin M, Candiotti K
Anesth Analg. 2016; 123(4):836-43.
PMID: 27258073
PMC: 6482381.
DOI: 10.1213/ANE.0000000000001417.
Opioid-induced constipation: advances and clinical guidance.
Nelson A, Camilleri M
Ther Adv Chronic Dis. 2016; 7(2):121-34.
PMID: 26977281
PMC: 4772344.
DOI: 10.1177/2040622315627801.
Reversal agents in anaesthesia and critical care.
Pani N, Dongare P, Mishra R
Indian J Anaesth. 2015; 59(10):664-9.
PMID: 26644615
PMC: 4645356.
DOI: 10.4103/0019-5049.167484.
Developments in managing severe chronic pain: role of oxycodone-naloxone extended release.
Fanelli G, Fanelli A
Drug Des Devel Ther. 2015; 9:3811-6.
PMID: 26229442
PMC: 4516191.
DOI: 10.2147/DDDT.S73561.